the energy in a polysaccharide is stored in glycogen.
where is the energy in a polysaccharide stored?
glycogen
any disruption to this system results in a glycogen storage disease. there are currently 2 subcategories of glycogen storage diseases in horses: type 1 polysaccharide storage myopathy, glycogen branching enzyme deficiency, and type 2 polysaccharide storage myopathy.





























section::::pathophysiology of glycogen storage disorders and sub-typing of pssm.:type 1 pssm.
equine polysaccharide storage myopathy
vaccines evoke an immune response to an antigen, and the immune system reacts by producing t cells and antibodies. the t cells remember the antigen so that if the body encounters it later, antibodies can be produced by b cells to break down the antigen. for bacteria with a polysaccharide coating, the immune response creates b cells independent of t cell stimulation. by conjugating the polysaccharide to a protein carrier, a t cell response can be induced. normally, polysaccharides by themselves cannot be loaded onto the major histocompatibility complex (mhc) of antigen presenting cells (apc) because mhc can only bind peptides. in the case of a conjugate vaccine, the carrier peptide linked to the polysaccharide target antigen is able to be presented on the mhc molecule and the t cell can be activated. this improves the vaccine as t cells stimulate a more vigorous immune response and also promote a more rapid and long-lasting immunologic memory. the conjugation of polysaccharide target antigen to the carrier protein also increases efficiency of the vaccine as a non conjugated vaccine against the polysaccharide antigen is not effective in young children. the immune systems of young children are not able to recognize the antigen as the polysaccharide covering disguises the antigen. by combining the bacterial polysaccharide with another antigen, the immune system is able to respond.
conjugate vaccine